AC Immune Said It Received Fda Fast Track Designation For ACI-24.060 Anti-amyloid-beta (Abeta) Active Immunotherapy To Treat Alzheimer's Disease
Portfolio Pulse from Charles Gross
AC Immune has received FDA Fast Track designation for its ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy for the treatment of Alzheimer's disease.
August 04, 2023 | 3:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AC Immune's stock may see positive movement due to the FDA Fast Track designation for its Alzheimer's treatment.
FDA Fast Track designation is a significant regulatory milestone that can expedite the development and review of a drug. This news is directly related to AC Immune and its Alzheimer's treatment, which is likely to positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100